Specific areas to be
addressed include patient selection, including types of PID most
appropriate for allogeneic HCT approaches; HCT preparative regimens,
including myeloablative versus nonmyeloablative regimens; alternative
donor sources, including cord blood sources; issues in prophylaxis and
treatment of Graft-Versus-Host disease specific to the PID population;
and methods and procedures for the study of immune reconstitution in
these patients. Please note: Conference attendance is by invitation
only.
